Revenue segments as reported by the company.

Premiums

Services

Investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefits

Operating costs

Depreciation and amortization

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Humana

Humana Inc. engages in the provision of health insurance services. The firm operates through the following segments: Retail, Group and Specialty and Healthcare Services. The Retail segment consists of products sold on a retail basis to individuals including medical and supplemental plans such as Medicare, and State-based contracts. The Group and Specialty segment contains employer group fully-insured commercial medical products and specialty health insurance benefits marketed to individuals and groups, including dental, vision, military services and other supplemental health & voluntary insurance. The Healthcare Services segment offers services such as pharmacy solutions, provider services, clinical care, predictive modeling and informatics to other Humana businesses, as well as external health plan members, and other employers. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Humana exceeds earnings expectations, focuses on value-based care growth

Humana's strong financial performance and growth in value-based care position the company well for future success. Addressing audit error rates, uncertainties around RADV, and managing costs are key challenges. Opportunities in recruiting, revenue growth, and strategic partnerships offer avenues for further growth.

Humana exceeds Q1 expectations, eyes industry growth amidst challenges

Humana's strong Q1 performance and strategic decisions position it well for growth
Challenges like rate disruptions and Medicaid redeterminations require close monitoring
Opportunities in industry growth, member engagement, and benefit enhancements ahead
Commitment to long-term goals and high-quality service evident in company's outlook

Humana meets Q2 expectations, eyes growth in MA platform

Humana's Q2 performance met expectations with a focus on MA platform growth and disciplined investments.
Challenges include higher utilization in Medicare Advantage and broad-based medical cost trends.
Strategic benefits adjustments and competitive positioning present opportunities for growth and margin expansion.
Expectations for 2024 include maintaining market share, offsetting costs, and achieving strong membership growth.

Humana surpasses Q3 earnings expectations, eyes $37 EPS target

Humana's Q3 performance exceeded expectations, with strong membership growth and strategic initiatives driving future profitability.
While facing challenges in benefit ratios and regulatory changes, Humana remains focused on achieving long-term financial targets.
The company's commitment to operational excellence, membership growth, and pricing actions positions it for sustained success.
Strategic partnerships and risk management efforts showcase Humana's resilience and adaptability in a dynamic healthcare landscape.

Humana faces challenges from rising costs but eyes long-term growth

Humana's Q4 2023 earnings call highlighted challenges from increased medical costs and utilization trends impacting financial performance and outlook.
Despite disappointments in short-term results, the company remains confident in the long-term attractiveness of the Medicare Advantage sector.
Strategic efforts to restore margins, address utilization drivers, and engage with providers reflect a proactive approach to managing industry dynamics.
Balancing profitability with membership growth through benefit adjustments and pricing actions is crucial for Humana's sustainable financial performance.

Humana reports solid Q1 performance, eyes margin recovery in 2025

Humana's Q1 2024 earnings call highlighted a strong start to the year, challenges in the industry for 2025, and a focus on margin recovery and growth opportunities. The company remains confident in its outlook, emphasizing pricing discipline and maintaining a strong value proposition in the market.

Humana surpasses Q2 expectations, addresses cost pressures for growth

Humana's Q2 2024 performance exceeded expectations, driven by strong Medicare business and growth in Medicaid and primary care segments.
Challenges such as medical cost pressures were addressed through mitigation measures, while opportunities lie in strategic initiatives and long-term planning.
The company's focus on value, disciplined cost management, and operational efficiency position it well for sustained growth and value creation.

Humana surpasses Q3 expectations, eyes growth through efficiency and investments

Humana's Q3 performance exceeded expectations, with a focus on balancing earnings and investments. The company is strategically positioned to drive growth through membership expansion and operational efficiency. Challenges include managing costs and understanding market dynamics, with opportunities in improving Stars ratings and expanding senior care services.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Humana's (HUM) revenues and membership gain on strong Medicare business. However, high expenses hurt.

Humana's (HUM) Medicare Business Aids, High Costs Persist

Humana (HUM) expands its footprint in New Jersey to facilitate the locals with better healthcare solutions.

Humana Penetrates Further in New Jersey Via PPO, HMO Plan

Cigna

UnitedHealth Group

Shares of Humana Inc. HUM, -0.97% fell 1.0% in midday trading, to pace the declines in its health care-sector peers, after BMO Capital analyst Matt Borsch downgraded the health-care benefits plan company, citing a re-rating of companies given political and health policy uncertainty.

Humana, UnitedHealth downgraded while Cigna upgraded as part of hedge against health policy uncertainty

Anthem

Growth in government and pharmacy benefit management businesses as well as share buybacks should enhance the third-quarter earnings of health insurers.

3 Health Insurance Stocks Poised to Beat on Earnings in Q3

Humana’s new digital health hub in Boston has the look and feel of a tech start-up, and that is very much the point.

Behind the scenes at Humana's new digital health unit in Boston

"I really want to encourage competition because I think competition creates innovation, and when you create innovation everyone wins," Humana CEO Bruce Broussard says.

Humana CEO: Competition and innovation lower drug prices better than just putting a cap on them

Humana (HUM) collaborates with Seniorlink to unveil Virtual Care Team pilot for offering its Medicare Advantage members an improved healthcare management.

Humana and Seniorlink to Serve Medicare Advantage Members

Humana (HUM) collaborates with Iora Health to strengthen its Medicare Advantage network across Texas, Georgia and Arizona.

Humana (HUM) Ties Up to Boost Medicare Advantage Network

Humana (HUM) teams up with McLaren Physician Partners to provide in-network access to its members in Michigan.

Humana Ties Up to Enhance Facilities for Members in Michigan

Allergan

Centene

WellCare Health Plans

Hedge funds continue to rotate out of tech stocks and into health care despite increased regulatory threats to the sector.

Hedge Funds Pile Into Health Care

Let's see if Humana (HUM) stock is a good choice for value-oriented investors right now from multiple angles.

Should Value Investors Consider Humana (HUM) Stock Now?

Banking high on its strong Medicare business and strategic buyouts, Humana (HUM) shows potential to reap benefits for investors, partly offset by high costs.

Why is It Worth Holding Humana (HUM) in Your Portfolio?

Humana (HUM) CEO, Bruce Broussard on Q2 2019 Results - Earnings Call Transcript

Humana stock surged early Wednesday after Humana earnings blew away second-quarter estimates on Medicare Advantage strength.
The post Humana Earnings Growth Accelerates On Medicare Advantage; Stock Jumps appeared first on Investor's Business Daily.

Humana Earnings Growth Accelerates On Medicare Advantage; Stock Jumps

Humana's (HUM) second-quarter earnings gain from Medicare Advantage membership growth.

Humana's (HUM) Earnings and Revenues Beat Estimates in Q2

Health insurer Humana raised its 2019 profit forecast on Wednesday and posted second-quarter earnings ahead of Street estimates.

Humana raises 2019 profit forecast on back of second-quarter beat

Humana (NYSE: HUM) reported second-quarter earnings of $6.05 per share, which beat the analyst consensus estimate of $5.30 by 14.15%.

Humana Trades Higher After Q2 Earnings Beat

Shares of Humana Inc. HUM, +1.25% jumped 2.3% in premarket trading Tuesday, after the health care company reported second-quarter profit and revenue that rose above expectations and provided an upbeat full-year outlook.

Humana's stock jumps after profit and revenue rise above expectations

Humana (NYSE: HUM) unveils its next round of earnings this Wednesday, July 31. Get prepared with Benzinga's ultimate preview for Humana's Q2 earnings.

Humana Q2 Earnings Preview

Amedisys

Charles River Laboratories

PRA Health Sciences

Teladoc

Healthcare stocks like HUM, AMED, CRL, TDOC and PRAH are likely to benefit from higher membership and revenues in the second quarter.

Healthcare Stock Q2 Earnings Due on Jul 31: HUM, AMED & More

Humana's (HUM) second-quarter earnings are likely to gain traction from a solid revenue stream.

Is a Beat in the Cards for Humana's (HUM) Earnings in Q2?

After many regulatory disturbances and overhang of the drug rebate ban proposal, a repeal of it is a breather for health insurers.

Health Insurers Rejoice on Pullback of Drug Rebate Plan

AmerisourceBergen

The Trump administration announced Thursday that it's deciding to withdraw its proposal to eliminate rebates from government drug plans.

News for Humana Stock (HUM)